title: Enteral and parenteral anti-endotoxin treatment in experimental colitis.
abstract: Systemic endotoxemia has been described in ulcerative colitis and Crohn's disease and shown to correlate positively with disease activity and the extent of intestinal ulceration. This study evaluated the efficacy of antibiotic and anti-endotoxic treatment in reducing systemic endotoxemia in a hapten-induced rat model of colitis. Enteral administration of paromomycin was associated with a significant reduction in systemic endotoxin concentrations (7.4 +/- 1.2 pg/ml) when compared with controls (39.8 +/- 12.6 pg/ml; p = 0.032). Intravenous injection of taurolidine was also found to significantly reduce systemic endotoxemia (3.1 +/- 1.3 pg/ml) in comparison with controls receiving saline injection (17.5 +/- 4.2 pg/ml; p = 0.008). Enteral neomycin, parenteral polymyxin or metronidazole and cefuroxime were ineffective anti-endotoxin treatments in this model. Enteral paromomycin or parenteral tauro-lidine therapy are potential methods of preventing and treating systemic endotoxemia in patients with inflammatory bowel disease.
authors.affiliation: Department of Surgery, Queen's University of Belfast, Northern Ireland, UK.
authors.forename: K R
authors.initials: KR
authors.lastname: Gardiner
authors.forename: N H
authors.initials: NH
authors.lastname: Anderson
authors.forename: M D
authors.initials: MD
authors.lastname: McCaigue
authors.forename: P J
authors.initials: PJ
authors.lastname: Erwin
authors.forename: M I
authors.initials: MI
authors.lastname: Halliday
authors.forename: B J
authors.initials: BJ
authors.lastname: Rowlands
mesh_terms: D000818:Animals; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D000992:Antitoxins / Q000627:therapeutic use*; D001835:Body Weight; D002444:Cefuroxime / Q000627:therapeutic use; D003092:Colitis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D004731:Endotoxins / Q000378:metabolism; D004750:Enteral Nutrition; D007275:Injections, Intravenous; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D009929:Organ Size; D010288:Parenteral Nutrition; D010303:Paromomycin / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013654:Taurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013829:Thiadiazines / Q000627:therapeutic use
chemical_list: D000891:Anti-Infective Agents, Local; D000992:Antitoxins; D004731:Endotoxins; D011113:Polymyxins; D013829:Thiadiazines; D008795:Metronidazole; D013654:Taurine; D010303:Paromomycin; C012566:taurolidine; D009355:Neomycin; D002444:Cefuroxime